2006 issue 2


Volume 15, issue 2

Review article

Glycine transporters - a potential target ofpharmacological intervention in the treatment of schizophrenia

Dominik Strzelecki1, Jolanta Rabe-Jabłońska1
1. Kliniki Zaburzeń Afektywnych i Psychiatrii Młodzieżowej Uniwersytetu Medycznego w Łodzi
Postępy Psychiatrii i Neurologii 2006; 15 (2): 105-117
Keywords: glycine, glycine transporters, glutamatergic system, schizophrenia


Objectives. Information is presented concerning glycine transporters (GlyT) and possibilities of modulating their function in order to attain beneficial clinical effects.

Background. Glycine, a co-agonist of the glutamatergic NMDA receptor, was found to have a beneficial effect on negative and cognitive symptoms in patients with schizophrenia. Further substances are presently sought that would have a wider spectrum of action and more pronounced therapeutic effects than glycine. Sarcosine and its derivatives, as well as the so-called second generation GlyT inhibitors with a different chemical structure seem to be at present the most promising drugs.

Address for correspondence:
Dr Dominik Strzelecki, Klinika Zaburzeń Afektywnych i Psychiatrii Młodzieżowej Uniwersytetu Medycznego, Centralny Szpital Kliniczny, ul. Czechosłowacka 8/10, 92-216 Łódź